PDT 2.0: The Future of Prescription Digital Therapeutics

Prescription digital therapeutics were the centre of all attention in the past years with millions of funding dollars flowing in with the promise of a bright future.  

Recent events, like big players going bankrupt and companies in the DTx/PDT industry laying off staff owing to declining revenues or have raised doubts and cut down capital investment  in PDTs.  

This, coupled with low rates of doctors prescribing and patients actually using these technologies has created a rather challenging climate. However, some PDT companies are standing tall and proving their business case in the context of the new reality. We still firmly believe in the viability and promise of PDTs.

 In this meeting, we will discuss: 

• Revised business models as a PDT - what does go to market look like in 2024? 

• How can patient and HCP adoption be scaled effectively and who owns the charge? 

• What are some important lessons learned and what should be avoided in future?